NDA submitted for exenatide once weekly for type 2 diabetes treatment - MPR
Links shared publicly online about this topic.
- 2,066total visits
NDA submitted for exenatide once weekly for type 2 diabetes treatment - MPR
empr.com —
Amylin Pharmaceuticals, Eli Lilly and Company, and Alkermes, Inc. announced that a New Drug Application (NDA) for exenatide once weekly has been submitted to the FDA as a subcutaneous injectable treatment of type 2 diabetes.
View full resource at empr.com
Tags: Diabetes Type 2 Medication, Diabetes Medication, Type 2 Diabetes, Drug, Pharma, FDA, Byetta, Eli Lilly and Company
Most Recently Shared on May 5, 2009 at 5:14 pm By:
MPR News: NDA submitted for exenatide once weekly for type 2 diabetes treatment: Amylin Pharmaceuticals.. http://tinyurl.com/chuvnu
Advertisement
